Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/molecular-diagnostics-patent-landscape-patent-landscape/ · Patsnap · data cut-off 2026-08-31 · downloaded from the live page
Patent Landscape · Molecular DiagnosticsMolecular diagnostics patents: mapping who holds the claims and what's still open
- 16.9% concentration at the top. The five leading assignees combine for 1,552 of 9,189 records in scope, with a long tail of single- and few-filing entrants behind them.
- Filing peaked in 2017 at 568. Volume has since eased, with 2021's 431 records giving way to 311 by 2024 — a -28% move over that span, before the 18-month publication lag makes later years look artificially light.
- Core claim space sits in two IPC subclasses. C12Q (56.3%) and G01N (39.1%) of all records dominate; bioinformatics (G16B, 9.6%) and bioreactor apparatus (C12M, 5.9%) are comparatively thin.
9,189
Published Records
17%
Top-5 Share of All Records
-28%
Filing Growth 2021→2024
US
Leading Jurisdiction
Filing growth compares 2021 (431 records) with 2024 (311) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 9,189 records in scope (CR5), not by the ranked leaders only.
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview
What the molecular diagnostics patent record shows
Molecular diagnostics covers the intersection of nucleic acid detection, sample handling and clinical measurement — from integrated cartridge devices to bioinformatics pipelines that interpret assay output. The dataset behind this page spans 9,189 published records filed or published between 2015 and the 2026 cut-off, drawn from filings that reference patient samples, device interfaces, detection sensitivity and related clinical measurement concepts alongside core molecular diagnostic assay language.
Filing activity peaked in 2017 and has eased since, though the most recent two to three years are understated because publication typically lags filing by about 18 months. Ownership is only moderately concentrated: the leading assignees account for a meaningful but not dominant share of the field, and most of the 100 ranked companies hold single-digit counts of the total.
Filing volume and technology composition, 2017–2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Molecular Diagnostics Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The Numbers
Filing trends and technology composition
Two views of the same 9,189-record dataset: filing volume over time, and where records sit across IPC subclasses. Because a single record can carry several IPC codes, the composition shares add to more than 100%.
Filing trend, 2017–2026
Filings ran at 568 in 2017, the peak year in the series. By 2021 the count was 431, falling to 311 in 2024 — a decline of 28% over that three-year window. 2025 and 2026 figures (down to 44 in the partial latest year) reflect publication lag rather than a real drop in filing activity.
Technology composition by IPC subclass
C12Q (enzymes/DNA measuring and testing) touches 56.3% of records and G01N (material analysis and testing) touches 39.1%, together forming the backbone of the field. C12N (microorganisms and genetic engineering, 14.0%), B01L (lab apparatus, 11.7%) and G16B (bioinformatics, 9.6%) mark the secondary layers where assay biology, hardware and data interpretation claims sit.
Shares are the percentage of the 9,189 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Molecular Diagnostics Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Molecular Diagnostics Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about molecular diagnostics patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
The most-cited records in the field
Representative Patent
US5922591A — Integrated nucleic acid diagnostic device
AFFYMETRIX, INC. A DELAWARE CORPORATION
The present invention provides a miniaturized integrated nucleic acid diagnostic device and system. The device is generally capable of performing one or more sample acquisition and preparation operations, in combination with one or more sample analysis operations, integrating several or all of sample acquisition and storage, sample preparation and sample analysis within a single unit. It is useful in nucleic acid based diagnostic applications and de novo sequencing applications.Filed by Affymetrix; cited 1,555 times, the second-most-cited record in this dataset behind a related Affymetrix filing cited 1,986 times.
Highest-cited molecular diagnostics patents
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5856174A | Integrated nucleic acid diagnostic device | 1,986 |
| 2 | US5922591A | Integrated nucleic acid diagnostic device | 1,555 |
| 3 | US6168948B1 | Miniaturized genetic analysis systems and methods | 1,175 |
| 4 | US6379929B1 | Chip-based isothermal amplification devices and methods | 906 |
| 5 | US6043080A | Integrated nucleic acid diagnostic device | 716 |
| 6 | US20020022261A1 | Miniaturized genetic analysis systems and methods | 609 |
| 7 | US6197595B1 | Integrated nucleic acid diagnostic device | 603 |
| 8 | WO1997002357A1 | Integrated nucleic acid diagnostic device | 534 |
| 9 | US6048695A | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support | 528 |
| 10 | US20190247050A1 | Integrated system for the infixion and retrieval of implants | 451 |
Citation counts reflect influence within the searched corpus and skew toward older filings; they are not a measure of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Molecular Diagnostics Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the data means for filing and freedom-to-operate decisions
Three patterns emerge from the concentration, trend and citation data that matter for anyone deciding where to file next or who to watch.
Concentration
16.9%
of 9,189 records held by top 5 assignees
Ownership is broad, not dominated by one player
The leading assignee holds 625 records, but the top five combined reach only 16.9% of the 9,189 records in scope. That leaves the bulk of filing activity spread across the other 95 ranked companies and beyond, many with single-digit counts.
Freedom-to-operate work needs to look past the household names.
Trend
-28%
filing change, 2021 to 2024
Volume has cooled from its 2017 peak
Filings fell from 431 in 2021 to 311 in 2024, a 28% decline over that window, after peaking at 568 in 2017. That is a real, complete-year comparison — later years in the dataset are still filling in due to publication lag and should not be read as a further drop.
Treat 2025-2026 counts as provisional, not a trend signal.
Composition
56.3% / 9.6%
C12Q share vs. G16B share of records
Assay chemistry is crowded; bioinformatics is thinner
C12Q claims sit on 56.3% of the 9,189 records, making core nucleic acid measuring and testing the densest claim space in the field. G16B, the bioinformatics subclass, touches only 9.6% — a smaller footprint relative to the volume of diagnostic data these systems now generate.
Interpretation and pipeline claims remain comparatively open.
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to molecular diagnostics patent landscape, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Molecular Diagnostics Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who is filing, and where the activity is quiet
The ranked assignee list covers 100 companies and institutions; it is the full ranking the dataset returns, not a curated top tier. Recent-year momentum data shows most named leaders with flat or falling filing counts in the latest year, consistent with the broader cooling since 2017.
Leader
625 records
top-ranked assignee
A single leader well ahead of the field
The top-ranked assignee holds 625 records, more than three times the fifth-place count of 184. That gap suggests a long-running, sustained filing programme rather than a recent surge.
Fifth place sits at 184; tenth place at 106 — the drop-off is steep.
Momentum
+200% YoY
fastest-growing filer in latest year (small base)
Momentum is scattered, not concentrated
One recent entrant shows +200% year-on-year growth, but off a base of just 3 records in the latest year. Several longer-established institutional filers show flat or zero counts in the same period, more a function of publication lag than a stop in research.
Read latest-year momentum figures alongside the low absolute counts behind them.
Co-filing
10 pairs
co-assignee relationships identified
Collaboration is limited but real
Ten co-assignee pairs appear in the dataset, with the strongest pairing co-filing 86 records together. That points to a small number of durable institutional partnerships rather than a broadly collaborative field.
Co-filing is the exception here, not the norm.
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| Magnolia Medical Technologies, Inc. | 3 | +200% |
| The Regents of the University of California | 1 | 0% |
| The Board of Trustees of the Leland Stanford Junior University | 1 | -50% |
| Koninklijke Philips N.V. | 0 | — |
| ZymoGenetics, Inc. | 0 | — |
| Genomic Health, Inc. | 0 | — |
| The General Hospital Corporation | 0 | -100% |
| Dana-Farber Cancer Institute, Inc. | 0 | -100% |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Molecular Diagnostics Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, whitespace filing, or tracking a competitor.
Check freedom-to-operate against the cited leaders
The most-cited records, including the Affymetrix integrated diagnostic device family, sit at the centre of the field's citation graph. Any new device-integration claim should be checked against these before drafting.
Explore citation trees in EurekaScope claims in the under-claimed IPC branches
Bioinformatics (G16B) and bioreactor apparatus (C12M) carry lower filing density than core assay chemistry, which may leave room for narrower, defensible claims.
Run a whitespace search in EurekaTrack the leading assignee's recent filings
With 625 records and a wide gap to fifth place, the top assignee's continuing filing behaviour is a useful early signal for where the field moves next.
Set up assignee monitoring in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Molecular Diagnostics Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions about molecular diagnostics patents
Across the 9,189 records in this dataset, one assignee leads with 625 records, well ahead of the fifth-ranked company at 184 and tenth place at 106. The top five combined account for 16.9% of all records in scope, so while there is a clear leader, ownership is not tightly concentrated — the remaining 95 ranked companies and many unranked filers make up the majority of activity. Anyone assessing competitive position should look at the full ranked list rather than assuming the leader dominates the space.
Filing peaked in 2017 at 568 records and has declined since, with 2021's 431 records falling to 311 by 2024 — a 28% decrease over that three-year, fully-published window. Figures for 2025 and 2026 look much lower still, but that reflects the roughly 18-month lag between filing and publication, not a genuine collapse in activity. The fair comparison point is 2021 to 2024, and even that shows a real cooling from the 2017 peak.
C12Q, covering measuring and testing methods involving enzymes and DNA, appears in 56.3% of the 9,189 records, making it the single densest claim area. G01N, material analysis and testing, follows at 39.1%. Secondary areas include C12N (microorganisms and genetic engineering, 14.0%), B01L (lab apparatus, 11.7%) and G16B (bioinformatics, 9.6%) — since records often carry multiple IPC codes, these percentages overlap rather than sum to 100%.
The IPC composition data shows bioinformatics (G16B, 9.6% of records) and bioreactor/enzyme apparatus (C12M, 5.9%) carry noticeably lower filing density than core assay chemistry and material analysis claims. That does not guarantee an area is easy to file in, but it does suggest less occupied claim space around data-interpretation pipelines and integrated bioreactor hardware compared to the crowded C12Q and G01N territory. A targeted search within those subclasses is a reasonable starting point before drafting new claims.
US5922591A, assigned to Affymetrix and issued in 1999, covers an integrated nucleic acid diagnostic device combining sample acquisition, preparation and analysis within a single unit — it is cited 1,555 times, among the most-cited records in this dataset. Its claims touch the core architecture of cartridge-style, sample-to-answer diagnostic devices, which is why device-integration filings in this space routinely need to check against it and its related family members. Designing around it typically means separating functions across modules or using a materially different sample-preparation approach rather than replicating the single-unit integration it describes.
Answers are grounded in the same dataset. Derived from a Patsnap search on Molecular Diagnostics Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Molecular Diagnostics Patent Landscape in depth with Eureka
Go past this page: query the whole molecular diagnostics patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.